S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.18 (+0.34%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.18 (+0.34%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.18 (+0.34%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.18 (+0.34%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

$2.20
+0.17 (+8.37%)
(As of 11:10 AM ET)
Compare
Today's Range
$2.00
$2.22
50-Day Range
$0.80
$2.20
52-Week Range
$0.65
$2.41
Volume
1.64 million shs
Average Volume
2.14 million shs
Market Capitalization
$268.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.4% Upside
$3.50 Price Target
Short Interest
Healthy
2.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.84mentions of X4 Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$12,269 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

197th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

28th out of 167 stocks


XFOR stock logo

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
What 5 Analyst Ratings Have To Say About X4 Pharmaceuticals
See More Headlines

XFOR Price History

XFOR Company Calendar

Last Earnings
3/21/2023
Today
6/01/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XFOR
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+72.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-93,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$0.42 per share

Miscellaneous

Free Float
120,887,000
Market Cap
$248.09 million
Optionable
Not Optionable
Beta
0.70

Key Executives

  • Paula S. RaganPaula S. Ragan
    President, Chief Executive Officer & Director
  • Mary DiBiase
    Chief Operating Officer
  • Adam S. MostafaAdam S. Mostafa
    Chief Financial Officer & Treasurer
  • Murray Willis Stewart
    Independent Director & Chief Medical Officer
  • Art Taveras
    Chief Scientific Officer













XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings
or view top-rated stocks.

What is X4 Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 1 year price targets for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 72.4% from the stock's current price.
View analysts price targets for XFOR
or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2023?

X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR shares have increased by 104.4% and is now trading at $2.03.
View the best growth stocks for 2023 here
.

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XFOR earnings forecast
.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06.

What ETFs hold X4 Pharmaceuticals' stock?

ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Simplify Propel Opportunities ETF (SURI) and

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.72%), AXA S.A. (3.60%), Geode Capital Management LLC (0.91%), Schonfeld Strategic Advisors LLC (0.85%), Ghost Tree Capital LLC (0.70%) and JPMorgan Chase & Co. (0.51%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Paula Ragan and Renato Skerlj.
View institutional ownership trends
.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $2.03.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $248.09 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -